The company that brought the world its first approved CRISPR-based therapy, CRISPR Therapeutics, has raised $100K in new capital. Known for its pioneering work in gene editing, the firm celebrated the historic approval of CASGEVY® in late 2023, a treatment for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
CRISPR Therapeutics has evolved significantly since its inception over a decade ago, advancing a diverse portfolio of product candidates across hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. The Swiss-headquartered company, with R&D operations in Boston and San Francisco, continues to leverage Nobel Prize-winning technology and strategic partnerships, including one with Vertex Pharmaceuticals, to develop potentially transformative medicines.













